Cargando…
New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350207/ https://www.ncbi.nlm.nih.gov/pubmed/29886840 http://dx.doi.org/10.2174/1872312812666180611113656 |
_version_ | 1783390407548207104 |
---|---|
author | Gunduz, Mithat Argikar, Upendra A. Cirello, Amanda L. Dumouchel, Jennifer L. |
author_facet | Gunduz, Mithat Argikar, Upendra A. Cirello, Amanda L. Dumouchel, Jennifer L. |
author_sort | Gunduz, Mithat |
collection | PubMed |
description | BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose ma-jor developability concerns. To date, multiple in vitro assays have been published to assess the risk asso-ciated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safe-ty remains poor. METHODS: In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as “safe,” “warning,” or “withdrawn” with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key interme-diates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s). RESULTS: Our results were in line with reported values in the literature. Our assay could be used in discov-ery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented. CONCLUSION: While the compounds tested from “withdrawn” and “warning category” all formed the glu-tathione adduct in buffer, none from “safe” category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative alde-hyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest. |
format | Online Article Text |
id | pubmed-6350207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-63502072019-02-22 New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation Gunduz, Mithat Argikar, Upendra A. Cirello, Amanda L. Dumouchel, Jennifer L. Drug Metab Lett Article BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose ma-jor developability concerns. To date, multiple in vitro assays have been published to assess the risk asso-ciated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safe-ty remains poor. METHODS: In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as “safe,” “warning,” or “withdrawn” with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key interme-diates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s). RESULTS: Our results were in line with reported values in the literature. Our assay could be used in discov-ery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented. CONCLUSION: While the compounds tested from “withdrawn” and “warning category” all formed the glu-tathione adduct in buffer, none from “safe” category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative alde-hyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest. Bentham Science Publishers 2018-12 2018-12 /pmc/articles/PMC6350207/ /pubmed/29886840 http://dx.doi.org/10.2174/1872312812666180611113656 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Gunduz, Mithat Argikar, Upendra A. Cirello, Amanda L. Dumouchel, Jennifer L. New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title | New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title_full | New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title_fullStr | New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title_full_unstemmed | New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title_short | New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation |
title_sort | new perspectives on acyl glucuronide risk assessment in drug discovery: investigation of in vitro stability, in situ reactivity, and bioactivation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350207/ https://www.ncbi.nlm.nih.gov/pubmed/29886840 http://dx.doi.org/10.2174/1872312812666180611113656 |
work_keys_str_mv | AT gunduzmithat newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation AT argikarupendraa newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation AT cirelloamandal newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation AT dumoucheljenniferl newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation |